抗CD19 CAR T细胞治疗110例高危特征B细胞急性淋巴细胞白血病患者的疗效与安全性
该1/2期研究纳入115例CD19阳性B细胞急性淋巴细胞白血病患者,110例成功输注抗CD19 CAR T细胞。93%达形态学完全缓解,87%微小残留病转阴;1年无白血病生存率58%,总生存率64%。后续接受异基因造血干细胞移植者生存优于仅CAR T治疗者,但因非随机分配需确认。
要点
- 110例高危B-ALL患者输注抗CD19 CAR T后,93%达形态学完全缓解,87%微小残留病转阴。
- 1年无白血病生存率58%,1年总生存率64%,各高危亚组均见疗效。
- 后续接受allo-HSCT者LFS 76.9% vs 11.6%、OS 79.1% vs 32.0%,均显著更优(P<.0001)。
核心结论
- 抗CD19 CAR T细胞治疗在所有高危特征B-ALL亚组中安全有效。
- 后续allo-HSCT的获益因非随机分配需进一步确认。
研究设计与样本
- 1/2期研究,纳入115例CD19阳性B-ALL患者,110例成功输注抗CD19 CAR T细胞。
- 75例(73.5%)非随机选择后续接受allo-HSCT。
- 试验注册号NCT03173417。
主要发现
- 93%患者达形态学完全缓解,87%微小残留病转阴。
- 110例患者1年无白血病生存率58%,1年总生存率64%。
- 后续接受allo-HSCT者较仅CAR T治疗者LFS 76.9% vs 11.6%(P<.0001;95%CI 11.6-108.4)、OS 79.1% vs 32.0%(P<.0001;95%CI 0.02-0.22)显著更优。
- 多因素分析证实allo-HSCT与更好结局相关(风险比16.546;95%CI 5.499-49.786)。
- TP53突变与更差结局相关(风险比0.235;95%CI 0.089-0.619)。
关键数值与推荐
- 形态学完全缓解率93%,微小残留病阴性率87%。
- 1年LFS 58%,1年OS 64%(110例患者)。
- allo-HSCT组 vs 仅CAR T组:LFS 76.9% vs 11.6%(P<.0001),OS 79.1% vs 32.0%(P<.0001)。
临床怎么用
- 抗CD19 CAR T细胞治疗可用于伴高危特征(BCR-ABL阳性、TP53突变、髓外病变包括中枢神经系统白血病或移植后复发)的B-ALL患者。
- 作者指出后续allo-HSCT的获益因非随机分配需进一步确认。
局限性
- 后续allo-HSCT的获益需进一步确认,因分配为非随机。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Anti-CD19 chimeric antigen receptor (CAR) T-cell therapy is effective in patients with advanced B-cell acute lymphoblastic leukemia (B-ALL). However, efficacy data is sparse in subgroups of patients with high-risk features such as BCR-ABL+, TP53 mutation, extramedullary disease (including central nervous system leukemia) or posttransplant relapse. It is also uncertain whether there is an added benefit of transplantation after anti-CD19 CAR T-cell therapy. We conducted a phase 1/2 study of 115 enrolled patients with CD19+ B-ALL. A total of 110 patients were successfully infused with anti-CD19 CAR T cells. In all, 93% of patients achieved a morphologic complete remission, and 87% became negative for minimal residual disease. Efficacy was seen across all subgroups. One-year leukemia-free survival (LFS) was 58%, and 1-year overall survival (OS) was 64% for the 110 patients. Seventy-five nonrandomly selected patients (73.5%) subsequently received an allogeneic hematopoietic stem cell transplant (allo-HSCT). LFS (76.9% vs 11.6%; P < .0001; 95% confidence interval [CI], 11.6-108.4) and OS (79.1% vs 32.0%; P < .0001; 95% CI, 0.02-0.22) were significantly better among patients who subsequently received allo-HSCT compared with those receiving CAR T-cell therapy alone. This was confirmed in multivariable analyses (hazard ratio, 16.546; 95% CI, 5.499-49.786). Another variate that correlated with worse outcomes was TP53 mutation (hazard ratio, 0.235; 95% CI, 0.089-0.619). There were no differences in complete remission rate, OS, or LFS between groups of patients age 2 to 14 years or age older than 14 years. Most patients had only mild cytokine release syndrome and neurotoxicity. Our data indicate that anti-CD19 CAR T-cell therapy is safe and effective in all B-ALL subgroups that have high-risk features. The benefit of a subsequent allo-HSCT requires confirmation because of nonrandom allocation. This trial was registered at www.clinicaltrials.gov as #NCT03173417.
引用
- Zhang X, Lu XA, Yang J, et al. Efficacy and safety of anti-CD19 CAR T-cell therapy in 110 patients with B-cell acute lymphoblastic leukemia with high-risk features. Blood Adv. 2020. PMID: 32453841. doi:10.1182/bloodadvances.2020001466
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。